Filing Details

Accession Number:
0001213900-24-035720
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2024-04-24 14:07:17
Reporting Period:
2024-04-19
Accepted Time:
2024-04-24 14:07:17
Original Submission Date:
2024-04-23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1711754 Inmune Bio Inc. INMB Biological Products, (No Disgnostic Substances) (2836) 475205835
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1767084 Scott Juda C/O Inmune Bio Inc.
225 Ne Mizner Blvd., Suite 640
Boca Raton FL 33432
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-04-19 29,603 $8.32 66,603 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (right to buy) Acquisiton 2024-04-19 29,603 $0.13 29,603 $9.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
29,603 2024-04-24 No 4 P Direct
Footnotes
  1. The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.